| HS Code | 669543 |
| Productname | PVC/PE/PVDC Triplex Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable |
| Productcategory | Pharmaceutical packaging material |
| Materialcomposition | Polyvinyl chloride (PVC), polyethylene (PE), polyvinylidene chloride (PVDC) |
| Construction | Triplex multilayer film |
| Grade | Pharma Grade |
| Dosageformcompatibility | Tablet, capsule, granule, injection, oral, injectable |
| Routeofadministration | Oral and injectable |
| Primaryuse | Blister packaging and pharmaceutical product protection |
| Barrierproperties | Moisture barrier, oxygen barrier, and light protection depending on formulation |
| Thickness | Typical 0.20 mm to 0.50 mm |
| Width | Typical 100 mm to 1000 mm |
| Rolllength | Typical 500 m to 2000 m |
| Surfacefinish | Glossy or matte, transparent or opaque options |
| Sealingcompatibility | Heat-sealable to aluminum or suitable lidding foil |
| Regulatorycompliance | GMP, ISO 9001, USP Class VI, FDA-compliant materials |
| Storageconditions | Dry, cool, clean area, away from direct sunlight |
| Shelflife | Typical 12 to 24 months |
| Packagingform | Rolls wrapped in protective film or foil |
As an accredited PVC/PE/PVDC Triplex Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Supplied in 25 kg rolls, polyethylene-wrapped and packed in fiber drums, palletized, sealed, batch-labeled, with certificate of analysis. |
| Container Loading (20′ FCL) | Container loading (20′ FCL): securely palletized, moisture-protected pharma-grade PVC/PE/PVDC triplex API for tablet, capsule, granule, injection, oral and injectable applications. |
| Shipping | PVC/PE/PVDC Triplex Pharma Grade API for oral and injectable use is shipped in sealed, clean, moisture-proof drums or foil-lined bags. Transport under controlled temperature, protected from light, humidity, and contamination. Label per GDP with batch, expiry, and storage conditions. Non-hazardous; handle as pharmaceutical material. |
| Storage | Store in a cool, dry, well-ventilated area at controlled room temperature (15–25°C), away from direct sunlight, heat, moisture, and ignition sources. Keep in tightly closed original packaging, protected from contamination, dust, odours, and physical damage. Maintain relative humidity below 60%. Store separately from incompatible materials. Use clean handling procedures, rotate stock, and follow pharmacopoeial and manufacturer storage requirements. |
| Shelf Life | Shelf life generally 24 months when stored in original sealed packaging, protected from moisture, heat, and light; confirm supplier COA. |
Thermoforming of the PVC/PE/PVDC triplex rollstock with a PVC core of 250 µm, an ethylene-based tie layer of 15–25 µm, and a PVDC topcoat applied at 60 g/m² is executed on Uhlmann BEC 500 and IMA PG 250 blister lines at plug-assist forming temperatures of 150–165°C. Water vapour transmission rates measured under ASTM F1249 at 38°C/90% RH for this configuration typically fall between 0.8 g/m²·day and 1.2 g/m²·day, which places the material in the moderate-high barrier class for immediate-release tablets; published data for specific formulations are limited and should be generated per batch. Compliance for direct contact under the European Pharmacopoeia is assessed against 3.1.1 and 3.1.2, while U.S. suitability testing follows USP <661.1> and USP <671> permeation classification. Forming station setup uses contact heating with a temperature differential across the forming pins of no more than ±5°C; excursions above 170°C induce surface blush from polyvinylidene chloride dehydrochlorination and create microporosity that is not visible under standard inline optical inspection. Sealing to 20 µm aluminum lidding foil coated with a 6–8 g/m² heat-seal lacquer is performed at 160–180°C with dwell times of 0.5–1.0 s; seal integrity is verified by vacuum leak testing per ASTM D3078 or equivalent. The terminal article is a push-through blister pack for immediate-release tablets, typically in 10 or 14 units per card, with the PVC layer providing formability and the PVDC layer providing the moisture and oxygen barrier. Processing on high-speed lines at 400–800 blisters per minute has shown that cavity thinning at the base corner must be held above 60 µm to prevent pinholes that would compromise the PVDC layer. Scrap from PVDC-coated web is not re-introduced into the PVC core above trace levels because PVDC thermally decomposes during extrusion and releases hydrochloric acid, which corrodes barrel and screw surfaces on conventional single-screw extruders with 24:1 L/D or greater.
| PVDC coating weight | PVC core | PE tie layer | Typical WVTR at 38°C/90% RH, ASTM F1249 | Dosage form application |
|---|---|---|---|---|
| 40 g/m² | 250 µm | 15–20 µm | 1.5–2.0 g/m²·day | Immediate-release tablets |
| 60 g/m² | 250 µm | 15–25 µm | 0.8–1.2 g/m²·day | Moisture-sensitive tablets and capsules |
| 90 g/m² | 200–250 µm | 15–20 µm | 0.4–0.8 g/m²·day | Desiccant-free generics and granule strip packs |
A desiccant-free blister architecture becomes technically justified when the drug substance exhibits a moisture uptake above 0.5% w/w at 60% RH and a hydrolysis-sensitive functional group, as in amoxicillin/clavulanate potassium, ramipril, or atorvastatin calcium. For these dosage forms, the PVDC coating is raised to 90 g/m² on a 250 µm PVC/PE core, giving a total film weight distribution in which the PVDC layer represents approximately 15–18% of total rollstock mass and the PE tie layer is held at 15–20 µm. The lidding foil is 20 µm aluminium with a heat-seal lacquer at 6–8 g/m², and a paper/polyester outer layer is added when child-resistant or senior-friendly formats are specified. Stability protocols follow ICH Q1A(R2), with storage at 40°C/75% RH for 6 months in primary pack without desiccant packets; water vapour ingress is measured by ASTM F1249 before and after flexing according to ASTM F392, because flex crack resistance of PVDC is the limiting factor at fold lines and seal corners. Production on high-speed lines uses nitrogen-purged sealing stations to reduce oxygen inclusion, with sealing temperature reduced to 160–170°C and dwell kept below 0.8 s to avoid heat-seal lacquer bleed into the push-through opening. The terminal finished product is a desiccant-free push-through blister for cardiovascular, anti-diabetic, and anti-infective generics, often in 7, 10, or 14-unit cards. The operational boundary is cavity depth: PVDC-coated PVC is not suitable for cold-form deep cavities greater than 10 mm; if a cavity deeper than 10 mm is required, aluminium-based cold-form laminate should be evaluated instead because PVDC will thin below the 60 µm critical corner thickness and lose barrier continuity.
When oral granules combine sodium bicarbonate, anhydrous citric acid, and polyvinylpyrrolidone binder, the PVDC surface is specified at 90 g/m² to prevent premature effervescence during storage. This configuration uses a PVC core of 200–250 µm and a PE tie layer of 15–20 µm, with the PVDC forming the primary moisture barrier on the product-contact side; lidding is a 25 µm aluminium/polyethylene laminate with a heat-seal layer activated at 120–140°C. Compliance for contact with oral solid formulations is based on Ph. Eur. 3.1.1, USP <661.1>, and specific migration testing according to EU 10/2011 where food-contact declarations are referenced by overseas buyers. Downstream conversion on strip-packaging machines such as Romaco Siebler or Bosch Strunck runs at 120–140°C jaw temperature, 0.3–0.5 MPa sealing pressure, and 0.6–1.2 s dwell. The product is a four-edge sealed unit-dose strip pack containing 0.5–5 g of granules; cavity dimensions are typically 25–45 mm long by 15–30 mm wide, and the PVDC layer is positioned as the inner barrier surface. Because effervescent formulations generate carbon dioxide in the presence of water, seal integrity must be confirmed by dye penetration testing after 48 h at 30°C/65% RH; pinholes below 20 µm are not detectable by standard vacuum decay and require helium leak testing. The terminal finished product type is a unit-dose strip pack for oral effervescent granules, pediatric powder sachets, and electrolyte granule formulations.
In stability protocol packaging, calendarized blister tooling with cavity matrices of 12–16 mm diameter and 6–8 mm depth is formed from the triplex at 150–160°C to avoid PVDC surface degradation. The layer ratio is 250 µm PVC / 15 µm PE / 60 g/m² PVDC, selected to balance barrier and formability over repeated tool changes on laboratory and pilot-scale blister machines. Stability batches are placed in chambers at 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH according to ICH Q1A(R2) and WHO stability guidance. The forming temperature is recorded at the plug contact surface, not in the machine setpoint, because PVDC-coated film exhibits a 5–8°C offset between preheat plate and film surface on high-speed rotary equipment. Seal integrity is tested after 0, 1, 3, and 6 months by vacuum leak testing and visual inspection for PVDC flaking or seal creep. The terminal product is a calendarized blister card used in clinical trial supplies and registration stability arms; each card typically contains 7, 14, or 28 units, with labeling space left uncoated to avoid print adhesion failures on PVDC. This scenario is sensitive to residual heat from sealing platens: if the platen temperature exceeds 180°C for more than 0.8 s, the PVDC coating adjacent to the seal area develops a brown discoloration that is detectable only under 10× magnification, and such cards are rejected under visual inspection criteria.
| Test property | Standard/Test method | Typical acceptance |
|---|---|---|
| Water vapour transmission rate | ASTM F1249 | ≤ 1.2 g/m²·day at 38°C/90% RH for 90 g/m² PVDC |
| Oxygen transmission rate | ASTM D3985 | ≤ 20 cm³/m²·day·atm for 90 g/m² PVDC |
| Flex durability | ASTM F392 | No visible pinholes after 10 flex cycles |
| Extractables profile | USP <661.1> | Meets monograph criteria for plastic packaging systems |
| Permeation classification | USP <671> | High barrier for oral solid dosage forms |
When dry powder inhaler capsules made from HPMC or gelatin are placed into PVC/PE/PVDC blister cavities, the PVDC coating is limited to 40–60 g/m² unless the formulation contains a highly hygroscopic carrier such as lactose monohydrate, which then requires 90 g/m². The film is formed into shallow cavities of 6–7 mm depth at 140–155°C; cavity diameter is matched to capsule size 3 or 4, and the PE tie layer is held at 15 µm to reduce neutral axis shifting during flexure. Sealing to 20 µm aluminium lidding foil at 150–160°C with 0.4–0.7 s dwell prevents heat damage to the capsule shell while maintaining a continuous seal around the cavity perimeter. Compliance with USP <671> and Ph. Eur. 3.1.1 is applied because the capsule shell does not provide an independent barrier; the PVDC film is the primary moisture control layer. The terminal product is a DPI capsule blister card, often in 10 or 30 dose counts, where the base web must not exceed 1.0 g/m²·day WVTR under ASTM F1249 or capsule brittleness and particle aggregation are observed. If the PVDC coating is below 40 g/m², published data for this specific configuration is limited, and a formal stability study under ICH Q1A(R2) plus ASTM F1249 after 1,000 mechanical flex cycles is required before release for production.
For oral lyophilized tablets with porous matrix densities of 0.2–0.4 g/cm³, a low-temperature forming window is selected to preserve cavity geometry and prevent PVDC surface cracking. A PVDC coating of 90 g/m² on a 200 µm PVC core with a 15 µm PE tie layer is used because the freeze-dried matrix collapses rapidly above 60% RH. Process parameters include plug temperature 140–150°C, sealing temperature 150–160°C, and 0.4–0.8 s dwell; blister cavities are 10–12 mm diameter and 3–5 mm depth. Compliance is tested per USP <661.1> extractables and ASTM F1249 WVTR. The terminal finished product is a push-through or peel-push blister pack for orally disintegrating or lyophilized tablets, with lidding foil 20 µm aluminium. The film should not be exposed to RH > 60% during storage because moisture adsorption onto the PVDC surface increases sealing variability and may cause steam blow-out at the seal interface. Production experience shows that PVDC-coated scrap cannot be re-introduced into the PVC core above trace levels because PVDC thermally decomposes in the extruder and generates hydrochloric acid, which corrodes barrel and screw surfaces. The triplex is not specified for primary contact with parenteral fluids; any injectable application would require a full extractables and leachables program under USP <1663> and is not an established field use.
Competitive PVC/PE/PVDC Triplex Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Specification of this material is not controlled by a single industry-wide model code. Commercial supply is defined by three structural variables: rigid PVC core thickness, polyethylene tie-layer grammage, and polyvinylidene chloride coating weight. The product string contains API as a supplier-specific grade code; it is not an active pharmaceutical ingredient. The material is supplied as a transparent, thermoformable web for pharmaceutical primary and secondary barrier applications in which moisture and oxygen ingress must remain below the limits established during stability studies for the packed dosage form. End users should verify that the drug master file, packaging qualification report, or supplier certificate of analysis uses the same designation.
Typical procurement specifications for oral solid dose blisters cite PVC core thicknesses of 200 µm, 250 µm, or 300 µm. The PE layer is specified as a continuous layer of 15–25 µm, coextruded or laminated between the PVC base and the PVDC barrier layer. PVDC is applied at coating weights from 40 g/m² to 120 g/m², with 60 g/m² and 90 g/m² predominating for moisture-sensitive tablet and capsule cavities in ICH Q1A/WHO stability Zones III and IV. Reel widths of 1200 mm to 1600 mm are standard on 76 mm or 152 mm cores. Thickness tolerance is certified at ±5% on the PVC core and ±10% on PVDC coating weight on widely available production lines. These values are representative of commercial film certificates of analysis; they do not replace a specific supplier specification because lot-to-lot variance and storage history alter the final barrier result.
The outer PVC surface is the forming face. The PVDC surface is the inner cavity face in contact with the drug product, except in secondary applications where PE may contact the device. Layer order is confirmed by infrared microscopy or differential scanning calorimetry on approval lots. Release criteria include film thickness, coating weight, residual vinyl chloride monomer below the applicable regulatory limit in 21 CFR 177.1970, water vapour transmission rate tested to ASTM F1249-20 at 38°C/90% RH, oxygen transmission rate to ASTM D3985-17 at 23°C/0% RH, and tensile elongation measured to ISO 527-3:2018. Published certificate-of-analysis values for 250 µm/25 µm/60 g/m² triplex typically show WVTR in the range 0.30–0.45 g/(m²·day) and OTR in the range 2–5 cm³/(m²·day·atm); for 90 g/m² PVDC the typical WVTR declines to 0.20–0.35 g/(m²·day) and OTR to 1.5–3.5 cm³/(m²·day·atm). These ranges are not universal because plasticizer type, PVDC comonomer ratio, and residual surfactant in the coating affect final barrier properties.
Interlayer adhesion determined by ASTM F904 is typically 2–5 N/15 mm before forming and should not fall below 1 N/15 mm at the cavity corner after forming. Dimensional stability under machine-direction tension is maintained below 60°C. Film storage above 30°C at relative humidity above 60% requires preconditioning because absorbed moisture on the PVDC surface can create seal blisters.
On continuous-motion blister thermoforming lines, the PVC forming face is heated to 110–140°C and the PVDC surface is held away from hot plates. PVDC thermal degradation accelerates above 150°C, producing brown discoloration and microcracking. Plug-assist temperature is maintained at 40–60°C with plug velocity 0.5–1.2 m/s. Cavity wall thickness reduction is controlled between 30% and 50% of the starting web; deep-cavity draw ratios above 1.5:1 typically require thicker PVC cores or a higher-elongation PE tie grade to prevent corner pinholing. These values are derived from public machine builder and film supplier processing bulletins, not from a single regulatory filing.
The PE interlayer functions primarily as a stress-decoupling and adhesion-promoting zone. Direct PVC/PVDC duplex films can fail during deep drawing because the elongation at break of PVDC is lower than the local elongation of the PVC cavity corner. In a triplex construction, the 15–25 µm PE layer permits relative displacement between the PVC and the PVDC, reducing crack nucleation during the forming cycle. Commercial PVDC aqueous coatings are copolymers of vinylidene chloride with methyl acrylate or acrylonitrile; higher vinylidene chloride content lowers permeability but increases brittleness. The PE tie layer partially compensates for this embrittlement in triplex constructions.
The PE layer also retards migration of PVC plasticiser into the PVDC layer. Plasticiser migration increases PVDC free volume and raises water vapour permeability; a continuous PE tie layer at 20 µm is generally sufficient to reduce this effect over the intended room-temperature shelf life, though the exact transport rate depends on plasticizer chemistry and temperature excursions. This improvement is not an absolute barrier gain. The PE layer adds a slightly more moisture-permeable zone than a direct, crack-free PVDC coating would provide. The triplex is selected when forming robustness and pinhole reduction outweigh a marginal WVTR penalty. In practice, a 60 g/m² duplex film that develops corner microcracks can have a local WVTR above 2 g/(m²·day) at the cavity corners, while a triplex of the same nominal coating weight maintains bulk WVTR in the 0.30–0.45 g/(m²·day) range because cracking is suppressed. This difference is measurable by dye-penetration testing and corner-section scanning electron microscopy on production samples.
For tablets and capsules, the film is used as the bottom web of push-through and peelable blister cavities. It is compatible with standard aluminium lidding foil sealed at 170–200°C, 0.5–1.0 s dwell, and 0.3–0.6 N/mm² seal pressure. Peel strengths measured by ASTM F88/F88M are typically 6–12 N/15 mm for clean peelable lidding. Values below 4 N/15 mm may create incomplete seals at high-speed filling. The PVDC face is not normally heat-sealable without a lacquered lidding foil; in secondary tray applications where the PE surface is used as the sealant, the seal temperature range is lower at 120–140°C because polyethylene has lower thermal resistance.
For granules, the triplex can be used for unit-dose cavities when granule size and flow allow reproducible fill. Granule applications are less common than tablet or capsule blisters because granule bulk densities and flowability often demand shallow, high-opening cavities. If a stick-pack or sachet format is required, this triplex web is not the first-choice sealant film because its stiffness is higher than laminated PE/PET/aluminium structures. Fines may require particle-retention lidding or reduced seal pressure because powder contamination on the seal area lowers peel strength by 30–50% in some production campaigns.
For injectable products, primary contact with liquid injectable formulations is generally not specified for flexible PVC/PE/PVDC because plasticiser migration, pH-related hydrolysis of the PVDC barrier, and steam-sterilization incompatibility impose unacceptable risk. The material is instead used in secondary containment trays for vials, pre-filled syringes, and medical device kits where the PVDC layer reduces oxygen ingress to the tray cavity during shelf life. If a supplier qualification seeks to use the triplex as a primary cavity for a lyophilised or dry injectable, the application requires extractables and leachables assessment under USP <1663> and USP <1664> and stability under ICH Q1A; published data for this specific configuration is limited, and the burden of compatibility evidence rests on the applicant.
The transparent triplex does not provide ultraviolet protection unless a UV-absorbing additive is incorporated into the PVC core. Light-sensitive tablets, capsules, or injectable components therefore require opaque lidding, secondary cartoning, or an additional UV-blocking overwrap. Direct contact with alkaline liquids above pH 8.0 should be avoided because PVDC undergoes dehydrochlorination under alkaline hydrolytic conditions.
Reported values in the following table are representative industrial ranges for flat webs, not formed cavity films. Formed cavity barrier is lower because thickness reduction and corner orientation increase permeation. Oxygen barrier of PVDC is humidity-dependent; OTR at 23°C/0% RH is lower than OTR at 23°C/80% RH. Stability protocols should therefore use formed blisters at multiple humidity conditions, not only flat-sheet 0% RH values.
| Construction | Typical total thickness | WVTR 38°C/90% RH | OTR 23°C/0% RH | Forming behaviour |
|---|---|---|---|---|
| Monolayer PVC | 250 µm | 3.0–3.5 g/(m²·day) | 150–250 cm³/(m²·day·atm) | Thermoformable; no PVDC barrier |
| PVC/PVDC duplex 60 g/m² | 250 µm plus coating | 0.35–0.50 g/(m²·day) | 3–8 cm³/(m²·day·atm) | Corner cracking risk above draw ratio 1.2:1 |
| PVC/PE/PVDC triplex 60 g/m² | 250 µm/25 µm plus coating | 0.30–0.45 g/(m²·day) | 2–5 cm³/(m²·day·atm) | Stress-decoupled; deep-cavity capable |
| PVC/PE/PVDC triplex 90 g/m² | 250 µm/25 µm plus coating | 0.20–0.35 g/(m²·day) | 1.5–3.5 cm³/(m²·day·atm) | Stress-decoupled; lower barrier gain after forming |
| Cold-form aluminium foil | 60–100 µm foil | <0.01 g/(m²·day) | <0.05 cm³/(m²·day·atm) | No heat-forming; high seal force required |
Compliance for this triplex is established through a matrix of polymer-specific food-contact and pharmaceutical packaging standards. The FDA references apply to the polymeric components; pharmaceutical quality management is addressed by ISO 15378:2017. The barrier methods are destructive or time-intensive, so release testing is often reduced after initial process validation based on supplier batch data and incoming identity testing.
| Regulatory reference | Scope | Application to triplex |
|---|---|---|
| 21 CFR 177.1970 | Vinyl chloride polymers | PVC core polymer and residual vinyl chloride monomer |
| 21 CFR 177.1520 | Olefin polymers | PE tie layer |
| 21 CFR 177.1630 | Polyvinylidene chloride polymers | PVDC barrier coating |
| USP <661.1> | Plastic materials of construction | Physicochemical suitability for packaging components |
| USP <661.2> | Plastic packaging systems | Drug product packaging system qualification |
| ISO 15378:2017 | GMP for primary packaging materials | Supplier quality system and batch traceability |
| ASTM F1249-20 | WVTR by modulated infrared sensor | Flat-web release and formed-cavity stability |
| ASTM D3985-17 | OTR by coulometric sensor | Oxygen barrier after forming |
| ISO 527-3:2018 | Tensile properties of films and sheets | Elongation at break for thermoforming robustness |
The position of PVC/PE/PVDC in the barrier hierarchy is defined by measured WVTR and OTR limits. At equal PVDC coating weight, a triplex has higher WVTR and OTR than PCTFE laminates in the 38°C/90% RH condition. A PCTFE laminate at 100 µm can achieve WVTR below 0.05 g/(m²·day); PVDC at 90 g/m² remains above 0.20 g/(m²·day). The triplex nonetheless thermoforms on standard contact-heating blister machines without the higher forming temperatures and more rigid handling required by some PCTFE laminates. Cold-form aluminium foil achieves essentially absolute barrier but loses transparent product inspection and requires larger cavity footprint and higher sealing forces. The selection of PVC/PE/PVDC is therefore driven by a combination of moisture threshold, machine availability, product visual appearance, and cost structure. For drug products requiring WVTR below 0.10 g/(m²·day), this material is not appropriate without additional desiccant in the cavity or an aluminium overwrap.
Rolls should be stored at 15–25°C and 30–50% RH in the original moisture-barrier bag. Cold storage below 5°C is not recommended because condensation upon opening can alter PVDC surface conductivity and generate seal defects. The film is intended for non-autoclavable applications; steam sterilization above 121°C is outside the qualified envelope. Avoid corona re-treatment on the PVDC face; corona treatment of the PE surface should not exceed 38–42 dyn/cm wetting tension, measured by ASTM D2578-17, because higher surface oxidation can increase seal initiation temperature and reduce peel reproducibility.